207940:KRXSamsung Biologics Co.,Ltd. Analysis

Samsung Biologics is trading at KRW 1,518,000, well above its DCF‑derived fair value of roughly KRW 850,000, implying a ~32% premium and signaling potential overvaluation. Technicals show a bullish MACD histogram (+8,483) and a 20‑day SMA (KRW 1,393,550) above the 50‑day SMA, yet the RSI of 62 suggests the stock is edging into overbought territory and sits just below the identified resistance of KRW 1,537,000. The equity exhibits ultra‑low beta (0.13) but a 30‑day volatility of over 60%, indicating price swings can be sharp despite limited systematic risk.
Fundamentally, the company delivers impressive growth – revenue up 25.8% YoY, operating margin near 46% and a solid ROE of 18.3% – backed by strong cash generation (KRW 2.33 tn operating cash flow) and a robust balance sheet, albeit with a high debt‑to‑equity ratio of 15. The recent ESG report underscores a strategic push toward sustainability, which may enhance client appeal in the CDMO market.